A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants

Phase 1 Recruiting 17 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Non-randomizedSequentialOpen-labelOther

Summary

This is a single-centre, open-label, fixed-sequence, 2-period study in healthy participants. The total study duration for each participant will be up to approximately 56 days, including a 28-day screening period, a 19-day assessment period (including Period 1 and Period 2), and a follow-up (FU) visit approximately 7 days after clinical research unit (CRU) discharge.

Timeline

Start: 2026-09-25
Primary completion: 2026-11-17
Completion: 2026-11-17

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mirdametinib	Small molecule	—	Oral
Subject	Probenecid	Small molecule	—	Oral

Indications

No indication recorded.